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Summary. In the present experiments we investigated en- 
dothelin (ET) receptors in the human coronary artery, 
and in ventricular and atrial muscle using quantitative r - 
ceptor autoradiography. Displacement of [125I]Sf6b (Sar- 
afotoxin S6b) (30 pM)- and [125I]ET-I (30 pM)-labeled 
binding sites was studied using ET-I, the ET A receptor 
selective ligand BQ-123 (cyclo[D-Asp-L-Pro-D-Val-L- 
Leu-D-Trp-]), and the ETB receptor selective ligand 
[Ala 1, 3, 11, 15]ET_l. 
Specific binding was more dense in atrium and coro- 
nary artery (relative optical density (r.o.d.): 0.14_+0.01 
and 0.16_+ 0.01, respectively) than in ventricular muscle 
(r.o.d.: 0.10_+0.0t). In the coronary artery, binding was es- 
pecially dense in the media. ET-1 displaced [125I]ET-1 
and [~25I]Sf6b monophasically in atrium, ventricle and 
coronary artery. [Alal'3'I~'IS]ET-I and BQ-123 displaced 
[125I]ET-1 and [125I]Sf6b-labeled sites biphasically in the 
ventricle and in the atrium. In the human coronary ar- 
tery, [AlaI'3'l~'lS]ET-1 and BQ-123 displaced [125IlET-1- 
labeled sites monophasically (plCs0:ET-1 (9.72+0.12) 
>BQ-123 (6.84+0.08)> [Alal'a'll'~5]ET-I (6.40_+0.12). 
In contrast, [AlaI'3'll'aS]ET-1 and BQ-123 displaced 
[125I]Sf6b-labeled coronary artery sites biphasicatly (high 
affinity plCs0: BQ-123, 9.03_+0.25; [Alal'3'l~'lS]ET-l, 
8.40_+0.14; low affinity pICs0: BQ-123, 7.24_+0.14; 
[Alal,3, ll,15]ET_l, 6.99_+0.09). 
These data indicate that both [125I]ET-1 and [125I] 
Sf6b-labeled ETA and ETB binding sites in human ven- 
tricular and atrial muscle. In the human coronary artery, 
both radioligands labeled ETA binding sites, but [125I] 
Sf6b also labeled a non-ET A, non-ETB binding site with 
relatively high affinity for both BQ-123 and [Ala 1'3'11'1s] 
ET-1. 
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Introduction 
Endothelin (ET) was originally described as a potent va- 
soconstrictor peptide (Yanigasawa et al. 1988). In addi- 
tion, Fozard and Wright (1988) described a vasodilatory 
effect, later found to be mediated, at least partially, by an 
endothelium-dependent mechanism involving the release 
of nitric oxide (NO; Fukuda et al. 1990) and/or prosta- 
cyclin (PGI2; De Nucci et al. 1990). In the heart, endo- 
thelin has been reported to elicit both positive inotropic 
(Moravec et al. 1989; Kitayoshi et al. 1989; Takanashi and 
Endoh 1991) and chronotropic (Ishikawa et al. 1989) ef- 
fects. Furthermore, endothelin induced mitogenesis of 
vascular smooth muscle cells (Komuro et al. 1988; Ohl- 
stein et al. 1992) and hypertrophy of myocardial cells 
(Shubeita et al. 1990) indicating that endothelin may play 
a role in the development of atherosclerosis and cardiac 
hypertrophy. 
Two distinct endothelin receptor subtypes (ETA; Arai 
et al. 1990 and ETB; Sakurai et al. 1990) have been 
cloned. In radioligand binding studies, the ET A receptor 
has somewhat higher affinity for ET-I in comparison 
with isopeptides like ET-3 or sarafotoxin S6b. The ET B 
receptor has almost equal affinity for all endothelins and 
sarafotoxin S6b (Arai et al. 1990; Sakurai et al. 1990; 
Saeki et al. 199/). The development of selective ligands 
that distinguish between these receptors has further 
helped to characterize the receptors present in various tis- 
sues such as the lungs (Nakamichi et al. 1992), kidneys 
(Nambi et al. 1992) and the myocardium (Molenaar et al. 
1993). In the diseased human heart obtained from heart 
transplant recipients, both ET A and ET B receptors have 
been described in the atrium and ventricle and in the 
atrioventricular conducting system, using in situ hybrid- 
ization and radioligand binding applying [125I]BQ3020, 
[125I][AlaI'3'll'lS]ET-1 (both with particularly high affini- 
ty for the ET B receptor) and the relatively unselective 
[125I]ET-1 as radioligands (Davenport et al. 1992; Mole- 
naar et al. 1992, 1993). 
In the present study we characterized endothelin re- 
ceptors in the human coronary artery, obtained from 
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healthy and diseased hearts. For compar ison we also 
studied endothel in receptors in the human ventricle and 
human atr ium. We used the ETA receptor selective li- 
gand BQ-123 (cyclo[D-Asp-~Pro-D-Val-L-Leu-D-Trp-];  
Ihara et al. 1991) and the ETB receptor selective l igand 
[Alal'3'lt'lS]ET-1 (Nakamichi  et al. 1992) and ET-1 to dis- 
place binding of  the relatively non-selective l igands 
[125I]ET-1 and [lzSI]Sf6b. A part  of  this study was pre- 
sented to the British Pharmacologica l  Society (Bax et al. 
1993). 
site-model, depending on the best fit (based on the Z 2 values, Grafit, 
Erithacus Software Ltd., Staines, UK). The slope factor of the displace- 
ment curves by [Ala~'S'~'~5]ET-1 and BQ-123 in the coronary artery 
were calculated according to De Lean et al. (1978), by fitting the curve 
in a one-receptor model. 
Compounds. [125I]ET-1 and [125IlSf6b (both with specific activity of 
2200 Ci/mmol) were purchased from ANAWA (Ztirich, Switzerland). 
ET-1, [Alal'S'll'tS]ET-I and BQ-123 were purchased from Neosystem 
S.A. (Strasbourg, France). 
Results 
Materials and methods 
Preparation of the tissue. A total of 16 human hearts was used in the 
present investigation. All experiments were approved by the Ethical 
Committee of the University Hospital Rotterdam 'Dijkzigt', The Neth- 
erlands. The hearts were provided by the Rotterdam Heart Valve Bank 
(Bio Implant Services/Eurotransplant Foundation, Leiden, The Nether- 
lands) after emoval of the aortic and pulmonary valves for valve trans- 
plantation. Twelve of the hearts were obtained from patients who died 
of non-cardiac disorders (6 cerebrovascular accident, 6 polytrauma; 7 
male, 5 female; age 7-55 years). These hearts were stored at 0-4 ° C in 
a sterile organ protecting solution immediately following circulatory ar- 
rest and arrived in the laboratory within 20 h after cardiac arrest. Four 
hearts were obtained from patients undergoing cardiac transplantation 
(2 dilating cardiomyopathy, included in the groups of cardiac atrium 
and ventricle and 2 end-stage coronary artery disease, included in the 
coronary artery group; all male; age 41- 55 years). After arrival in the 
laboratory, the right and left descending coronary artery and samples 
of free wall of right atrium and left ventricle (+ 1.5 cm 3) were removed 
and the vessels were cleaned of fat and connective tissue. All samples 
were embedded in M-1 embedding matrix (Lipshaw, Pittsburgh PA, 
USA) and frozen in liquid nitrogen. The tissue was kept at -70 °C until 
further use. Serial sections of 10 gm were cut on a micro-cryostat nd 
thaw-mounted on gelatin-coated glass slides and kept at -20°C until 
binding experiments. 
Autoradiographic protocol. The slides were thawed and subsequently 
preincubated for 15 min in a Tris-BSA buffer, pH 7.4. (Tris: tris(hydrox- 
ymethyl)-aminomethan; BSA: Bovine Serum Albumin; both from Sig- 
ma Chemical Co., St. Louis MO, USA). The tissue was then incubated, 
at room temperature, for 120 min in 10 ml Tris-BSA buffer containing 
either 30 pM [lzsI]ET-I or 30 pM [lZSI]Sf6b. The incubation buffer 
also contained chymostatin (2mg/1; Bachem, Bubendorf, Switzerland), 
leupeptin (4 rag/l; Sigma Chemical Co., St. Louis MO, USA), 
bacitracin (40 rag/l; Sigma, Buchs, Switzerland) and 5 mM MnC1 z. 
Non-specific binding was assessed in the presence of 0.3 p.M unlabeled 
ET-1. Displacement of radioligand binding was studied by adding unla- 
beled ET-1 (concentration range I pM-0.3 IxM), [Alal'3'll'lS]ET-1 
(concentration range 30 pM-10 ~M) or BQ-123 (concentration range 
3 pM-30 gM) to the radioligand containing buffer. After incubation, 
the slides were rinsed twice in ice-cold buffer for 5 min. The slides were 
then rapidly dried by exposing to a stream of cold air and subsequently 
apposed to [SH]Hyperfilm (Amersham, Buckinghamshire, UK) for 6 h. 
After exposure the films were developed (Kodak D19, Rochester, New 
York, USA), fixated and dried. In addition, we performed high resolu- 
tion autoradiography by placing emulsion-coated (Kodak NTB 3, Ro- 
chester, New York, USA) glass coverslips to the slides and exposed for 
18 h. The coverslip slides were developed (Kodak D19, Rochester, New 
York, USA) and fixated. Subsequently the tissue was stained with elas- 
tic-Van Gieson. Experiments (n = 7-14) were performed in two sepa- 
rate sessions. 
Analys& of the data. Binding on film was quantified ensitometrically 
using a computerized image analysis ystem (MCID Imaging Research, 
St. Catherines, Ontario, Canada). Displacement curves were analyzed 
for individual segments, generating competition curves for a one or two 
Specific binding of  [125I]Sf6b and [12SI]ET-1 in ventricu- 
lar and atr ial  muscle was homogeneously  distr ibuted over 
the tissue and specific binding was more dense in the atri-  
um and the coronary artery (relative optical density 
(r.o.d.): 0.14+0.01 and 0.16+_0.01 respectively) than in the 
ventricle (r.o.d.: 0.10+0.01; Fig. 1). In the coronary arte- 
ry, binding on f i lm consisted exclusively of  binding to the 
media, but coverslip high resolution autoradiography re- 
vealed also a signal in a thin adventit ial  layer and between 
media and the int imal hyperplasia. Label ing in the latter 
two regions of  the vessel consisted mainly of  non-specif ic 
binding, and did not show on [SH]Hyperf i lm (Fig. 2). 
ET-1 displaced [lzSI]Sf6b and [125I]ET-1 monophasi -  
cally in the ventricle (Fig. 3; pICs0 values of  the curves 
are shown in Table 1). [Alal'3'~I'IS]ET-1 and BQ-123 
displaced [~25I]ET-1 and [125I]Sf6b-labeled sites biphasi-  
cally in the ventricle. Assuming a two receptor model  to 
be present, the proport ion of  high-aff inity sites of  
BQ-123 (which should equal the proport ion  of  low affini- 
ty sites o f  [Alal'3'Jl'~SlET-1) as compared to the high af- 
f inity sites of  [Alal'3'l l ' IS]ET-1 (which should equal the 
proport ion  of  low aff inity sites of  BQ-123) was 53 +_3°70: 
47 +3% in the ventricle; percentages for separate curves: 
see Table 1). 
Also in the atr ium [t25IlSf6b and [125I]ET-1 were dis- 
placed monophas ica l ly  by ET-1, but biphasical ly by 
[Ala s, 3,11, I5]ET_ 1 and BQ- 123 (Fig. 4; pICso values of  the 
curves are shown in Table 2). In the atr ium, the propor-  
t ion of  high aff inity sites of  BQ-123 as compared to the 
high aff inity sites of  [Alat'33~'IS]ET-1 was 68+3070: 
32+3070 (percentages for separate curves: see Table 2). 
Table 1. Human ventricle, pICs0 ( -  Log ICs0 ) for the monophasic dis- 
placement by ET-I, and in case of biphasic displacement the high 
(pICs0 high) and/or low (pICso low) affinity value and proportion (% 
high, °70 low) of the affinity phases of [Alal'3'llAS]ET-1 and BQ-123 
[~25]ET-1 [125I]Sf6b 
ET-1 plCs0 a 10.16_+0.08 9.49+0.08 
[Alal'S'l~'15]ET-I plCs0 high 9.59_+0.34 9.48-+0.16 
% high 39.7 _+5.1 50.6 _+5.1 
pICs0 low 6.05 _+ 0.20 6.54 _+ 0.12 
% low 60.3 +_5.1 49.4 -+5.1 
BQ-123 pICs0 high b 7.04_+0.24 7.49+0.10 
% high b 50.1 -+5.6 49.4 _+14.3 
a Monophasic omplete displacement 
b Lower affinity phase could not be analyzed because plateau was 
reached 
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Fig. 1. Autoradiographs of total (A and B) and non-specific binding (C 
and D) of [125I]ET-l-labeled ventricular segments (three different pa- 
tients, A and C) and one [125I]ET-l-labeled atrial segment (B and D). 
Note differences in receptor density between ventricle on one hand and 
atrium and coronary artery (embedded in fat attached to the left ventri- 
cle: A and C, arrow) on the other hand. Scale bars: panel C, 4 mm; pan- 
el D, 0.5 mm 
In the human coronary artery, ET-1 displaced both 
[125I]Sf6b and [t25I]ET-I in a monophasic manner. 
[Alal'3'lt'IS]ET-1 and BQ-123 displaced [125I]ET-l-labeled 
sites monophasically in 6 and 7 segments respectively, out 
of 7 individually analyzed tissue segments. In contrast, 
[Alal'3'll'lS]ET-1 and BQ-123 displaced [125I]Sf6b-labeled 
Table 2. Human atrium, plCs0 ( -Log  ICs0 ) for the monophasic dis- 
placement by ET-1, and in case of biphasic displacement the high 
(pICs0 high) and/or low (pICs0 low) affinity value and proportion (07o 
high,% low) of the affinity phases of [Alal'3'l~'lS]ET-1 and BQ-123 
[125I]ET-1 [125I]Sf6b 
ET-I pIC5 ° a 9.61 _+ 0.04 8.95 _+ 0.07 
[AlaI'3'11'15]ET-1 pICso high 9.05_+0.33 9.36+0.09 
07o high 27.9 _+5.1 24.7 _+2.7 
pICso low 5.79 _+0.17 6.91_+0.05 
°70 low 72.1 -+5.1 75.3 +2.7 
BQ-123 pICso high b 6.67-+0.12 7.45+0.40 
070 high b 58.7 _+5.5 48.3 _+ 13.2 
a Monophasic omplete displacement 
b Lower affinity phase could not be analyzed because plateau was 
reached 
sites biphasically in 9 segments each, out of 14 individu- 
ally analyzed coronary artery segments. Also analysis of 
the mean curves in the coronary artery revealed a mono- 
phasic curve as the best fit for the displacement of [t25I] 
131115 ET-1 by [A la"  ' ]ET-1 and BQ-123, whereas the dis- 
125 1.3 11 15 placement of [ I]Sf6b by [A la"  ' ]ET-1 and BQ-123 
were both best described by a biphasic curve (Fig. 5). In 
addition, the slope factor (or pseudo Hill number) of the 
125 displacement curve of [ I]Sf6b by [AlaI'3'il'lS]ET-1 or 
BQ-123, when fitted to a monophasic model according to 
De Lean et al. (1978), was significantly lower (0.64_+0.09 
and 0.69_+0.11 respectively) than the slope of the dis- 
1 3 i1 15 placement curve by [A la"  ' ]ET-1 or BQ-123 of 
[125I]ET- 1 (0.95 _+ 0.08) and 1.27 + 0.14 respectively). The 
125 [ I]Sf6b-labeled proportion of receptors with high af- 
finity for both BQ-123 and [Alai'3'I1'lS]ET-1 was 
49-+4%: 51+4% when compared to the proportion of 
[125I]Sf6b-labeled- sites with 'low' affinity for BQ-123 
and [Alal'3'll'tS]ET-I. We observed no differences in re- 
ceptor density, affinity values or slope factors between 
healthy and diseased hearts. Therefore, the data refer to 
the mean of all ventricle, atrium or coronary artery sam- 
ples. 
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Fig. 2. Left panels: Autoradiography film of total (A) and non-specific 
(C) binding of one [125I]ET-l-labeled coronary artery segment, ob- 
tained from a patient undergoing a cardiac transplantation for 
ischaemic oronary artery disease. Right panels: High resolution auto- 
radiography (C) and light microscopy (elastic-Van Gieson staining, 40 ×, 
D) of the same coronary artery segment. Int, intima: a combination of 
intimal hyperplasia nd intimal fibrosis; M, media 
Discussion 
Both [~2SI]ET-1 and [~25I]Sf6b were found to label a 
mixed population of binding sites in human ventricle and 
atrium. Using [~zSI]ET-1, we found an apparently single 
receptor population in the human coronary artery with 
characteristics similar to one of the two receptors in the 
ventricle and atrium. However, the radioligand [125I]Sf6b 
also seemed to label a coronary artery site with binding 
characteristics different from the atrial and ventricular 
endothelin receptors. It has to be noted that non-specific 
binding was defined using unlabeled ET-1. In general, 
non-specific binding should preferably be determined us- 
ing a cold ligand, different from the radioligands [125I] 
125 ET-I and [ I]Sf6b. However, little is known about truly 
non-selective endothelin receptor ligands. Furthermore, 
1,3 tl 15 the maximum displacement by [Ala ' ' ]ET-1 and ET-I 
was similar for both [lzSI]ET-1- and [125I]Sf6b-binding in
atrium and in ventricle (Figs. 3, 4). In the coronary ar- 
tery, all three cold ligands (ET-I, [AlaI'3'lt'lS]ET-1, and 
BQ-123) caused a similar amount of total displacement 
both for [125I]ET-1 and [lzSI]Sf6b (Fig. 5). Taken togeth- 
er, this indicates that the use of ET-1 to define non-specif- 
ic binding is appropriate. 
Endothelin receptors in the ventricle and the atrium 
Endothelin has been shown to cause positive inotropic 
and/or chronotropic effects in the ventricle and atrium of 
several animal species (Kitayoshi et al. 1989; Ishikawa et 
al. 1988a, b) and man (Moravec et al. 1989; Davenport et 
al. 1989; Brodde et al. 1992). In the rabbit isolated papil- 
lary muscle, the positive inotropic response appeared to 
be mediated by the ET B receptor (Takanashi and Endoh 
1991), but the nature of the receptor involved in endo- 
thelin-induced rat myocyte hypertrophy and secretion of 
natriuretic peptide from rat myocytes (Shubeita et al. 
1990) thus far remains unknown. The human ventricle 
has recently been shown to contain both ET A and ETB 
receptors, e.g. by using BQ-123 and BQ-3020 (an ET B re- 
125 ceptor selective compound) to displace [ I]ET-l-labeled 
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Fig. 3. Human left ventricle. Displacement 
(% of total specific binding) of [125I]ET-1 
(panel A) and [~25I]Sf6b (panel B) by ET-I 
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Fig. 4. Human right atrium. Displacement 
(% of total specific binding) of [125I]ET-1 
(panel A) and [125I]Sf6b (panel B) by ET-1 
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Fig. 5. Human coronary artery. Displacement 
(% of total specific binding) of [~25I]ET-1 
(panel A) and [125I]Sf6b (panel B) by ET-1 
(e),  BQ-123 (11) and [Alal'3'tt'IS]ET-1 (A) 
Table 3. Human coronary artery, plCs0 (-Log ICso (mol/1)) for the monophasic displacement (plCso mono) or, in case of biphasic displacement, 
the high (plCs0 high) and low (plCs0 low) affinity value and proportion (% high, °70 low) of the affinity phases of [Alal'3'tl'tS]ET-I and BQ-123. 
Slope factor of the curves (or pseudo Hill number), see De Lean et al. (1978) 
[125I]ET-i Slope factor [125I]Sf6b Slope factor 
ET- 1 pICs0 9.72 ± 0.02 a 9.35 + 0.04 
[Alal,3,11JS]ET-1 plCso mono 6.40_+0.12 a 0.95±0.08 7.66_+0.06 b 0.64+0.09 
plCso high 8.40 ± 0.14 
% high 47.3 ±4.8 
plCs0 low 6.99 ___0.09 
% low 52.7 ±4.8 
BQ-123 plCs0 mono 6.84±0.08 a 1.27±0.14 7.82 +0.13 b 0.69___0.11 
plCso high 9.03 _+0.25 
°7o high 50.l +6.1 
plCs0 low 7.24±0.14 
% low 49.9 -+ 6.1 
a Monophasic omplete displacement 
b plC5 ° value when fitted to a monophasic model to calculate the slope factor of the curve 
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for both the ET A and ETB receptor (Molenaar et al. 
1993). These authors also found a (free wall) ventricular 
population of both ETA and ETB receptors in an ap- 
proximate percentage of 60 and 40%, respectively (pre- 
sent study 53 and 47070, respectively). In our study the 
pICs0 values of ET-1, [Alal'3'll'lS]ET-1 and BQ-123 also 
fitted with a mixed ETA/ETB receptor population. The 
high affinity of BQ-123 (pK D -~ 9), presumably for the 
ET A receptor, was however clearly higher in the study by 
Molenaar et al. (1993) than in our study (pICs0 ~-7). 
Other ET A receptor assays, however, have reported pICs0 
values for BQ-123 of approximately 7 (Nakamichi et al. 
1992) or 8 (Ihara et al. 1991). 
Also in the atrium we observed a mixed receptor pop- 
ulation that appeared to consist of both ET A and ET B 
receptors. In the right atrium, the proportion of ET A re- 
ceptors (68% ET A vs. 32°70 ETB receptors) was some- 
what higher than in the ventricle. This was possibly due 
to a higher density of atrial ETA receptors and similar 
density of ET B receptors, since the overall ET receptor 
density was higher in the atrium. Endothelin has previ- 
ously been shown to elicit positive inotropic responses in
the human isolated atrium (Davenport et al. 1989; 
Brodde et al. 1992). However, ET-1 did not cause positive 
inotropic affects in six strips obtained from the human 
ventricle strip that responded normally to (-)-isopre- 
naline (Davenport et al. 1989) and caused only very small 
inotropic effects in another study (Moravec et al. 1989). 
In this respect, it is of interest that the receptor density 
in the ventricle of several animal species has previously 
been found to correspond to the effectiveness of ET-1 in 
producing a positive inotropic effect (Takanashi and En- 
doh 1991). Functionally differential effects on human 
atrial and ventricular tissue have also been observed for 
5-hydroxytryptamine which produced a positive inotropic 
effect on the isolated atrium (Kaumann et al. 1991) which 
could not be shown in the ventricle (Jahnel et al. 1992; 
Schoemaker et al. 1992a, b). Therefore, one should be 
careful to extrapolate he clear positive inotropic response 
elicited by endothelin in the rabbit papillary muscle 
(Takanashi and Endoh 1991) and in the human atrium 
(Davenport et al. 1989; Brodde et al. 1992) to the human 
ventricle, until further functional experiments in the hu- 
man ventricle have been performed. 
Endothefin receptors in the coronary artery 
Endothelin was originally described as a vasoconstrictor 
peptide (Yanagisawa et al. 1988). Since then, various re- 
ports have appeared on the nature of this contractile re- 
ceptor. An ET A receptor appeared to be involved in the 
contractile response to ET-I of the porcine coronary ar- 
tery (Fukuroda et al. 1992), but a non-ET A receptor, dif- 
ferent from the ET n receptor, seemed to be involved as 
well (Harrison et al. 1992). This contention was based on 
the finding that ET-3 recognized a sarafotoxin $6c (selec- 
tive for the ET B receptor; Williams et al. 1991) sensitive 
receptor, which was not recognized by ET-I, thus ruling 
out the ET R receptor. ET-1 has also been shown to cause 
potent contractions of human coronary artery segments 
(Chester et al. 1989; Davenport et al. 1989; Hems6n et al. 
1990), but until now the nature of the endothelin receptor 
in this particular tissue remains unknown. 
The present results indicate that a receptor which 
shows similar affinities for ET-1, [Alal'3'tl'lS]ET-1 and 
BQ-123 as in the human ventricle and atrium is also pre- 
sent in the human coronary artery. Using in situ-hybrid- 
ization to show the presence of mRNA for the receptor, 
Molenaar et al. (1993) provided further evidence that this 
endothelin receptor in the human ventricle and atrium is 
of the ETA subtype. Considering the biphasic and shal- 
low displacement curves (Fig. 5), [125I]Sf6b also ap- 
peared to label another binding site with high affinity for 
both [AlaI'3'll'IS]ET-1 and BQ-123 (Table 3). This bind- 
ing site does not seem to be related to any of the thus far 
discovered endothelin receptors. Interestingly, unlabeled 
ET-1 completely displaces [12SI]Sf6b inding with high 
affinity, and thus also appears to have affinity for this 
'unknown' binding site. On the other hand, iodinated 
ET-I apparently does not bind to the 'unknown' binding 
site since ET-1, BQ-123 and [AlaI'3'll'lS]ET-1 all cause 
monophasic displacement of [125I]ET-1. Whether indeed 
this [125I]Sf6b-labeled binding site, showing high affinity 
for both BQ-123 and [Alal'3'II'lS]ET-I, constitutes a new 
endothelin receptor in blood vessels, requires further in- 
vestigation using other endothelin isopeptides like ET-3 
and sarafotoxin $6c, in radioligand assays as well as in 
functional experiments. Also the existence of different af- 
finity states for the same receptor, labeled by [125I]Sf6b, 
but not by [125I]ET-1, cannot be entirely excluded. This 
does however not apply to differences between high and 
low affinity phases for [Alal'3'~I'lS]ET-1 and BQ-123 in 
the atrium and ventricle since the differences of pICs0 
values appear too high for different affinity states of the 
same receptor (Tables 1, 2). On the other hand, vascular 
receptor heterogeneity has previously been suggested by 
Sumner et al. (1992), who observed that ET-3-induced 
contractions of the rabbit thoracic aorta were antago- 
nized by BQ-123 with an estimated pK B value of 8.3, 
whereas BQ-123 antagonized ET-l-induced contractile r - 
sponses of the same tissue with a - presumably ET A re- 
ceptor-related - pA  2 of 6.9. 
Endothelin receptors in the diseased heart 
When compared to healthy cardiac tissue (Bio Implant 
Services/Eurotransplant organ donor tissue), we ob- 
served no differences in atrial and ventricular endothelin 
receptor characteristics in diseased hearts (dilating car- 
diomyopathy, obtained from heart ransplant recipients). 
However, it has to be kept in mind that the numbers of 
diseased hearts investigated (n= 2) is too small to note 
possible subtle differences. Other investigators also failed 
to show a difference between healthy and diseased tissue 
(Eisenmenger's syndrome, ischemic heart disease; Mole- 
naar et al. 1993) in man. An experimentally induced con- 
gestive heart failure in dogs, however, was found to result 
in a downregulation f cardiac endothelin receptors, pos- 
sibly due to an increased plasma endothelin level (Fan et 
al. 1992). An increased plasma endothelin level has also 
been noticed in a variety of human cardiovascular (and 
non-cardiovascular) diseases in man (Miller et al. 1993). 
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In the human coronary artery obtained from cardiac 
transplantation patients for ischemic heart disease 
(n = 2), we have neither observed a higher density of re- 
ceptors nor different receptor characteristics. However, it 
has to be remarked that the pathological changes in coro- 
nary artery diseased transplantation hearts are merely the 
end-stage of a disease, present in the vasculature of many 
subjects who are generally considered healthy. 
In summary, we observed that both [125I]ET-1 and 
[125I]Sf6b were found to label a population of ET A and 
ETB binding sites in the human ventricle and atrium. Us- 
ing [125I]ET-1 we found a single receptor population in 
the human coronary artery with similar characteristics a
the ET A receptor in the ventricle and atrium. However, 
the radioligand [t25I]Sf6b also labeled a binding site with 
characteristics different from the atrial and ventricular 
endothelin receptors. Further experiments are needed to 
demonstrate whether this binding site is indeed a new en- 
dothelin receptor in the human coronary artery. 
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